NCT01631097View on ClinicalTrials.gov

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Hepatic Impairment
Interventions
DRUG

Tivozanib hydrochloride

Single oral capsule 1.5 mg tivozanib hydrochloride

Trial Locations (2)

Unknown

Miami

Orlando

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY